The VPAC 1 and VPAC 2 receptors for vasoactive intestinal polypeptide and the PAC 1 receptor for pituitary adenylate cyclase-activating polypeptide are members of a subfamily of G protein-coupled receptors (GPCRs). We recently reported that phospholipase D (PLD) activation by members of the rhodopsin group of GPCRs occurs by at least two routes, one of which seems to involve the small G protein ADP-ribosylation factor (ARF) and its physical association with GPCRs. Here we report that rat VPAC and PAC 1 receptors can also stimulate PLD (albeit less potently than adenylate cyclase) in transfected cells and also in cells where they are natively expressed. PLD responses of the VPAC receptors and the hop1 spice variant of the PAC 1 receptor but not its null form are sensitive to brefeldin A (BFA), an inhibitor of GTP exchange at ARF. The presence of the hop1 cassette in the rat PAC 1 receptor facilitates PLD activation in the absence of marked changes in ligand binding, receptor internalization, and adenylate cyclase activation, with some reduction in phospholipase C activation. Both VPAC 2 and PAC 1-hop1 (but not PAC 1-null ) receptors were shown to associate with immunoprecipitates directed against native or epitopetagged ARF. A chimeric construct of the VPAC 2 receptor body with intracellular loop 3 (i3) of the PAC 1-null receptor mediated BFA-insensitive activation of PLD, whereas the response of the corresponding PAC 1-hop1 construct was BFA-sensitive. Motifs in i3 of the PAC 1-hop1 receptor may act as critical determinants of coupling to ARF-dependent PLD activation by contributing to the GPCR:ARF interface.
the hop1 cassette in the rat PAC 1 receptor facilitates PLD activation in the absence of marked changes in ligand binding, receptor internalization, and adenylate cyclase activation, with some reduction in phospholipase C activation. Both VPAC 2 and PAC 1-hop1 (but not PAC 1-null ) receptors were shown to associate with immunoprecipitates directed against native or epitopetagged ARF. A chimeric construct of the VPAC 2 receptor body with intracellular loop 3 (i3) of the PAC 1-null receptor mediated BFA-insensitive activation of PLD, whereas the response of the corresponding PAC 1-hop1 construct was BFA-sensitive. Motifs in i3 of the PAC 1-hop1 receptor may act as critical determinants of coupling to ARF-dependent PLD activation by contributing to the GPCR:ARF interface.
G protein-coupled receptors (GPCRs) have been classified into a number of different families, according to functional criteria or to sequence homology (Probst et al., 1992; Ji et al., 1998) . One of the distinct families of GPCRs is that for large peptide hormones such as secretin, parathyroid hormone, glucagon, and glucagon-like peptide 1 (GLP-1). These receptors, which include the VPAC 1 and VPAC 2 receptors (for VIP/ PACAP) and the PAC 1 receptor (selective for PACAP) retain the architecture of seven transmembrane helices and the general principles of signal transduction common to all GPCRs (Segre and Goldring, 1993; Harmar and Lutz, 1994; Arimura and Shioda, 1995; Donnelly, 1997) . The rat VPAC 1 and VPAC 2 receptors were cloned by Ishihara et al. (1992) and Lutz et al. (1993) and were shown to activate adenylate cyclase (AC) and thereby raise intracellular cAMP levels (Ishihara et al., 1992; Lutz et al., 1993) . In some studies the VPAC 1 and VPAC 2 receptors have also been shown to elicit small inositol phosphate responses (MacKenzie et al., 1996; van Rampelbergh et al., 1997) . The closely related PAC 1 receptor (Arimura and Shioda, 1995) was cloned independently by six different laboratories (Hashimoto et al., 1993; Hosoya et al., 1993; Pisegna and Wank, 1993; Spengler et al., 1993; Svoboda et al., 1993) . The PAC 1 receptor couples to the activation of AC and phospholipase C (PLC) (Hashimoto et al., 1993; Hosoya et al., 1993; Morrow et al., 1993; Pisegna and Wank, 1993; Spengler et al., 1993; Svoboda et al., 1993) , and exists in at least six splice variants, a short form, PAC 1-null, and five variants with extra amino acid inserts in intracellular loop 3 (i3), including the PAC 1-hop1 variant investigated here (Spengler et al., 1993) . Splice variants of both the rat and human PAC 1 receptors may activate PLC with differing efficiency (Spengler et al., 1993; Pisegna and Wank, 1996) . The widespread importance of i3 in the coupling of GPCRs to guanine nucleotide-binding (G) proteins has been well established by many studies involving mutant and chimeric receptor constructs (Wess, 1997) .
The activation of phospholipase D (PLD) has been implicated in many key physiological processes (Exton, 1997) but has been little investigated for receptors of the secretin/parathyroid hormone receptor family. We report for the first time the stimulation of PLD by the VPAC 1 , VPAC 2 , PAC 1-null , and PAC 1-hop1 receptors at nanomolar concentrations of VIP/PACAP that could be physiologically relevant. Similar responses to those in transfected cells are seen in cells natively expressing VPAC 2 and PAC 1 receptors. Furthermore, we provide evidence that the hop-1 splicing insert in i3 of the PAC 1 receptor selectively facilitates receptor coupling to ARF-dependent PLD activation, but not other signaling pathways, and enables coimmunoprecipitation of the receptor with ARF (which could also be observed with the VPAC 2 receptor). tol, and [9,10- 3 H]palmitic acid were obtained from PerkinElmer Life Science Products, Dreiech, Germany. All peptides were from Novabiochem, Nottingham, UK, and all biochemicals were from Sigma, Poole, UK, unless otherwise stated. Any reagents with relatively lower aqueous solubility (such as brefeldin A or U 73122) were added to cell signaling assays from solutions in dimethylformamide. Corresponding additions of vehicle were made to control and test wells and were limited to a concentration of 0.3% (at which level no effects could be detected on any of the responses).
Experimental Procedures Materials

Generation of Stable Chinese Hamster Ovary (CHO) Cell Lines
cDNAs encoding the rat VPAC 1 , VPAC 2 , PAC 1-null , and PAC 1-hop1 receptors were introduced into the expression vector pcDNA1, containing the neomycin resistance gene (Invitrogen BV, Groningen, The Netherlands). CHO cells were transfected with the receptor plasmids using lipofectamine (Life Technologies). Forty-eight hours after transfection, geneticin (500 g/ml) was added to cells grown in Ham's F-12 nutrient media with 10% NCS, 100 U/ml penicillin, and 100 g/ml streptomycin to select for cells expressing constructs. Clonal cells were picked and growth was continued for 1 month in geneticin-containing media. Clonal lines expressing the different receptors were selected for their ability to stimulate cAMP production in response to VIP, PACAP, and other VIP-like peptides. The expression of the mRNA for the various receptors was also confirmed by Northern analysis (data not shown).
Construction of Chimeric Receptors
Chimeric receptors were made by replacement of the i3 domain of the rat VPAC 2 receptor with the i3 domains from either the short form or the hop-1 form of the rat PAC 1 receptor. Exchange sites were within transmembrane domain (tm) 5 and tm7 (Fig. 4) . This was achieved using cDNAs encoding the rat VPAC 2 receptor (R4, pBluescript) and the null (R7b, pBluescript) and hop1 (R7/9.1, pBluescript) splice variants of the rat PAC 1 receptor. The first domain exchange was made by using a conserved restriction (HincII) site in the region of the cDNAs encoding the fifth transmembrane region of the VPAC 2 and PAC 1 receptors. After digestion with HincII, the appropriate cDNA fragments were gel purified and then ligated with T4 DNA ligase (Promega, Southampton, UK). These were inserted into pBluescript for selection of appropriate clones by sequence analysis of the domain exchange region. The second domain exchange within tm7 was made by overlap extension polymerase chain reaction (PCR) mutagenesis (Huang et al., 1995) . The reaction was heated to 95°C for 5 min and then maintained at 80°C while adding 2.5 U of Pfu (Pyrococcus furiosus) polymerase (Stratagene, Amsterdam, The Netherlands), after which the reaction was put through 30 cycles with denaturing at 94°C (1 min), annealing at 57°C (1 min), and extension at 72°C (3 min). After the first round of PCR, 10-l samples were analyzed by electrophoresis. The remaining PCR reactions were purified by extracting with the Wizard cDNA purification system (Promega), and then in the second round of PCR amplification 1-l volumes of each appropriate extract were mixed and amplified using the flanking pBluescript primers under the same conditions as the first round of amplification. These were ligated into pBluescript for selection of appropriate clones by sequence analysis and then inserted into the expression vector pcDNA1 for functional expression in COS 7 cells.
Cell Culture and Transient Transfection of Receptor cDNAs
CHO cell lines stably expressing the VPAC 1 , VPAC 2 , PAC 1-null , and PAC 1-hop1 receptors were grown in 80-cm 2 flasks in Ham's modified F-12 medium containing 10% NCS, 300 g/ml geneticin, 100 U/ml penicillin, and 100 g/ml streptomycin, in a humidified atmosphere of 5% CO 2 and 95% O 2 at 37°C. GH 3 and ␣T3-1 cells were cultured as described previously (Johnson et al., 2000) . Confluent cultures were trypsinized and seeded into 12-well cell culture plates for assay of PLC or PLD activity, or 24-well plates for assay of cAMP production. COS 7 cells were grown in 175-cm 2 flasks in Dulbecco's modified Eagle's medium containing 10% NCS, 100 U/ml penicillin, and 100 g/ml streptomycin, in a humidified atmosphere of 5% CO 2 and 95% O 2 at 37°C. The cDNAs for the chimeric VPAC 2 /PAC 1-null and VPAC 2 /PAC 1-hop1 (VP/4/7b/2.1c and VP/4/7/2.1c, pcDNA1) receptors were transfected into COS 7 cells using 30 g of cDNA/6 ϫ 10 6 cells and DEAE dextran (Promega) or FuGENE 6 (Roche Diagnostics Ltd., Lewes, UK) as described previously MacKenzie et al., 2001 ).
Whole-Cell Ligand Binding
The density and affinity of ligand binding sites in the VPAC 1 VPAC 2 , PAC 1-null , and PAC 1-hop1 receptor-expressing cell lines were determined by nonlinear curve-fitting analysis of homologous displacement curves (Swillens, 1992) . This method allows calculation of the number and affinity of binding sites in circumstances (such as with ligands iodinated in-house) where the precise ligand specific activity is not known and therefore Scatchard type analysis is not possible. Experiments were carried out at 37°C using intact cells in 12-well plates. This enabled assessment of both cell-surface association and internalization of ligand, reflecting the cellular disposition of the receptors under near-physiological conditions. Cells were incubated in 0.5 ml of Medium 199 with 0.2% BSA, 30 g/ml bacitracin, and 10 g/ml aprotinin, plus 125 I-helodermin (for VPAC 1 /VPAC 2 receptors) or 125 I-PACAP-27 (for PAC 1 receptors), using 20,000 to 50,000 cpm/well.
125
I-Helodermin (approximately 770 Ci/mmol) was prepared by iodination using chloramine-T and purified by highperformance liquid chromatography according to methods described previously (Ogier et al., 1987) . Increasing concentrations of unlabeled helodermin/PACAP-27 were also present as required. Nonspecific binding was defined with 300 nM unlabeled helodermin or PACAP-27, respectively. The plates were incubated at 37°C for 20 min unless otherwise indicated. The assay was terminated by aspiration of the medium and the cells were washed three times with 0.5 ml of ice-cold EBSS containing 0.1% BSA. Externally bound ligand was dissociated by a 5-min wash with 0.5 ml of an ice-cold acid strip solution (0.2 M acetic acid/0.5 M NaCl) (Slice et al., 1994) . Internalized ligand was determined by solubilization of the cells after the acid strip wash using 1% Triton X-100 in 0.1 M NaOH. Protein content was determined using the bicinchoninic acid system (Pierce, Rockford, IL). After incubation of 125 I-PACAP-27 with PAC 1-null receptor-containing CHO cells, the integrity of the ligand was assessed by reverse-phase chromatography on C18-silica (Waters Ltd., Watford, UK) using an H 2 O/methanol gradient, containing 0.2% trifluoroacetic acid. After 30-min incubation at 37°C, 80 to 83% of the ligand in the extracellular medium and that released from the cells by hypotonic lysis in 10 mM formic acid still eluted as authentic 125 I-PACAP-27.
Determination of cAMP Production
CHO/COS 7 cells expressing the VPAC 1 , VPAC 2 , PAC 1-null , and PAC 1-hop1 receptors were preincubated for 10 min with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (500 M) and then stimulated with agonist (for 15 min). Intracellular cAMP levels were measured using a radioimmunoassay technique described previously Lutz et al., 1999 ).
Determination of [ 3 H]Inositol Phosphate Production
After 16-h labeling with 1 Ci/ml myo-[2- 
Measurement of [ 3 H]Phosphatidylbutanol ([ 3 H]PtdBut) Production
Cells in 12-well plates that had reached 80 to 100% confluence were placed in serum-free medium and labeled by incubation with 10 Ci/ml/well [9,10-3 H]palmitate (40 Ci/mmol) for 18 h before assay. PLD activity was monitored as the production of [ 3 H]PtdBut when cells were stimulated in the presence of 30 mM butan-1-ol (Mitchell et al., 1998) . Before stimulation, cells were washed twice with MEM containing fatty acid-free BSA (1%), before replacement with minimal essential medium containing 0.5% BSA. The assay (30 min) was started with addition of agonist and terminated by aspiration of the medium and addition of 0.5 ml of ice-cold methanol. Cells were homogenized and samples transferred to 2-ml glass vials, before chloroform and H 2 O were added to give a ratio of methanol/chloroform/H 2 O of 1:1:0.8. Samples were vortexed and left for 15 min and then spun for 8 min in a low-speed centrifuge to separate the aqueous and organic layers. The upper aqueous layer was removed and an aliquot of the lower organic phase was evaporated under vacuum at 30°C in a centrifugal evaporator (Jouan, Nottingham, UK). Lipids were redissolved in 50 l of chloroform/methanol (19:1) and separated by thin-layer chromatography on LK5D silica gel plates (Whatman, Maidstone, UK) using the upper phase of a mixture of 110 ml of ethyl acetate, 50 ml of 2,2,4-trimethylpentane, 20 ml of acetic acid, and 100 ml of water. The region of the thin-layer chromatography plate corresponding to [
3 H]PtdBut, as determined by authentic standards, was scraped into vials and the radioactivity was quantified by liquid scintillation counting.
Receptor:Small G Protein Coimmunoprecipitation Studies
Native ARF. Experiments to assess association of native ARF with the VPAC 2 receptor were carried out using the VPAC 2 receptorexpressing CHO cell line. Cells in Dulbecco's modified Eagle's medium were incubated for 10 min with/without 10 nM VIP before washing in cold EBSS and solubilization (30 min at 4°C) in 20 mM sodium HEPES (pH 7.5) with 1 mM sodium orthovanadate, 1 mM NaF, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 2 g/ml aprotinin, 4 g/ml leupeptin, 2 g/ml pepstatin A, 50 g/ml soybean trypsin inhibitor plus 5 mM CHAPS, 0.1% sodium cholate, and 1 M NaCl. Extracts were diluted 1:1 with the same buffer lacking salt but including 20% glycerol. After preclearing with protein G-Sepharose, samples were centrifuged at 12,000g for 30 min. Aliquots of supernatant were retained for ligand binding by polyethylene glycol 8000 (PEG) precipitation (see below), whereas others were incubated (16 h rolling at 4°C) with sheep anti-ARF1 98-112 immunoglobulin at 10 l/ml, with/without blocking peptide at 10 g/ml (Mitchell et al., 1998) or nonimmune sheep IgG (3 g/ml; Sigma) as control. Excess protein G-Sepharose was added to each tube and incubated with rolling for 3 h at 4°C before centrifugation (12,000g for 5 min). The pellet was washed twice with equivalent buffer before resuspension into similar buffer with the addition of (sonicated) phosphatidylcho- ]PtdBut production induced by 1 M VIP in VPAC 1 (Ⅺ) and VPAC 2 (f) receptor-expressing CHO cell lines and its lack of effect on cAMP production (F) in VPAC 2 receptor-expressing cells. Statistical significance of the inhibition was assessed by Mann-Whitney U test; *p Ͻ 0.05, **p Ͻ 0.01 (n ϭ 6 -8). E, specific 125 I-helodermin binding to ARF 1/3-directed immunoprecipitates in the VPAC 2 receptorexpressing CHO cell line. Solid columns show cells exposed to 100 nM VIP for 10 min before solubilization, whereas open columns show controls, not previously exposed to agonist. In some samples, excess antigenic peptide was supplied to block the antibody, as indicated.
line (Sigma) to 3 mg/ml. The suspension was aliquoted (100 l) into tubes with 400 l of 50 mM Tris-HCl (pH 7.4) containing 6.25 mM MgCl 2 , 1% BSA, 0.1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 0.5 mg/ml bacitracin, 7% glycerol, and 2 mg/ml phosphatidylcholine. Approximately 80,000 cpm of 125 I-helodermin was added per tube, with/without 1 M unlabeled helodermin to define nonspecific binding. Assays were incubated for 1 h on ice before the addition of 0.6 ml of 30% PEG and 0.1 ml of bovine ␥-globulin (0.1%). After mixing and standing on ice for 15 min, the samples were centrifuged at 12,000g for 20 min, the supernatant was aspirated, and the tube tips were removed for gamma-counting of the pellets.
Epitope-Tagged ARF. COS 7 cells were cotransfected with expression plasmids encoding the PAC 1-null and PAC 1-hop1 receptors and ARF1 with a carboxyl-terminal HA epitope tag (in pcDNA3 and pXS, respectively). Transfections were carried out with 8 g of receptor plasmid DNA, 2 g of ARF plasmid DNA, and 30 l of FuGENE 6/175-cm 2 flask. Seventy-two hours later, quiescent cells were washed in cold EBSS before solubilization (1 h on ice) in standard phosphate-buffered saline (PBS) with the same proteaseand phosphatase-inhibitors used for experiments with native ARF, plus 1% CHAPS. After preclearing with protein G-Sepharose, extracts were centrifuged at 12,000g for 30 min. Aliquots of supernatant were retained for binding and PEG precipitation, whereas others were incubated (16 h rolling at 4°C) with mouse monoclonal anti-HA IgG (clone 12CA5; Roche Diagnostics Ltd.) and/or control nonimmune mouse IgG to a total of 2 g/ml. Excess protein GSepharose was added and incubated with rolling for 3 h at 4°C before centrifugation. The pellet was washed with solubilization buffer and then with PBS before resuspension into PBS. Samples were aliquoted (100 l) into tubes with 400 l of PBS and final concentrations of 10 mM MgCl 2 and 0.2% BSA. Approximately 11,000 cpm of 125 I-PACAP-27 was added per tube, with/without 100 nM PACAP-38 to define nonspecific binding. After incubation for 1 h on ice, assays were terminated, and PEG precipitated and harvested as described above.
Results
VPAC 1 and VPAC 2 Receptors. The cell-surface expression of 125 I-helodermin binding sites and the internalization of ligand were measured in selected CHO cell clones expressing VPAC 1 and VPAC 2 receptors ( Fig. 1A ; Table 1 ). Cell surface VPAC 1 and VPAC 2 receptors showed high affinity for helodermin (approximately 1-3 nM), as did the recognition sites from which ligand had subsequently become internalized (presumably receptors that had been present at the cell surface). The amount of accumulated ligand in intracellular stores was consistently greater than that remaining on the cell surface after incubations of more than 5 to 10 min. The time course of 125 I-helodermin association with cell-surface VPAC 2 receptors and its subsequent internalization are illustrated in Fig. 1A , showing rapid equilibration of cellsurface binding to a steady state by 10 min and continuing extensive internalization reaching a maximum by 20 min. The time course of ligand binding in the VPAC 1 receptor CHO clone was not studied in detail. (Fig. 1 , B and C; Table 2 ). VIP elicited robust, concentration-dependent increases in cAMP production at VPAC 1 and VPAC 2 receptors (Fig. 1B) (Fig. 1C) . The potency of these PLD responses was considerably lower than that for cAMP responses of the receptors, but still in the low nanomolar range ( Table 2) . As with the cAMP responses, the maximal PLD response of the VPAC 1 receptor was less than that of the VPAC 2 receptor.
To assess whether the PLD responses might be downstream of the activation of G s or adenylate cyclase, [ 3 H]PtdBut production was measured in cells stimulated with 1 and 5 g/ml cholera toxin (16 h) or 1 and 5 M forskolin (during the 30-min assay). None of these stimuli caused any detectable increase in [ 3 H]PtdBut production, despite large control PLD responses to 1 M phorbol 12,13-dibutyrate being recorded in each assay (data not shown).
Receptors can activate PLD through many routes (Exton, 1997) , including pathways downstream of PLC activation or involving the small G proteins ARF and Rho (Mitchell et al., 1998) . Because PLC activation was undetectable in response to VIP in these cell lines, it seems unlikely that this is important in bringing about the PLD responses observed. In PLD responses of rhodopsin family GPCRs, sensitivity to BFA, an inhibitor of some ARF GTP-exchange factors, correlates closely with the involvement of ARF 1/3 in these responses, apparently through direct association with relevant receptors (Mitchell et al., 1998) . Figure 1D shows that BFA inhibited VPAC 1 and VPAC 2 receptor PLD responses with relatively high potency, yet was without effect on cAMP responses.
Coimmunoprecipitation experiments were carried out on solubilized extracts of the VPAC 2 receptor-containing CHO cells to assess any ARF:receptor interaction. ARF 1/3 was immunoprecipitated broadly as described previously (Mitchell et al., 1998) Figure 1E shows that specific binding of 125 I-helodermin was associated with ARF immunoprecipitates and this was considerably reduced when the ARF antibody was blocked with excess of the antigenic peptide or when nonimmune IgG was substituted. Brief preincubation with the agonist VIP seemed to facilitate ARF: receptor association. The affinity of solubilized, and presumably also immunoprecipitated receptors for ligand was reduced so it is not possible to reliably calculate the proportion of the receptors engaging with ARF. (Fig. 2, A and B; Table 3 ). The accumulation of ligand in both compartments of PAC 1-null and PAC 1-hop1 receptor CHO cells was inhibited with moderately high affinity (9-21 nM) by unlabeled PACAP-27 with no clear evidence for multiple components (mean Hill coefficient of 0.99 Ϯ 0.11 from all experiments). The time courses for cell surface association of 125 I-PACAP-27 and for the internalization of ligand bound to receptors were generally similar between PAC 1-null and PAC 1-hop1 receptors (Fig. 2, A and B) and to data from the VPAC 2 receptor (Fig. 1A) . The steady-state accumulation of 125 I-PACAP-27 into the intracellular compartment seemed to be slightly greater for the PAC 1-null receptor than for the PAC 1-hop1 receptor but neither this, nor slight differences in rates between the splice variants, were investigated further. (Fig. 2C) . Consistent with previous reports (Spengler et al., 1993; van Rampelbergh et al., 1997) (Fig. 3A) . The maximal evoked PLD response of the PAC 1-hop1 receptor was consistently around 3-fold that of the PAC 1-null receptor, in contrast to the pattern of their PLC responses. Time courses of these PLD responses showed no evidence of desensitization for at least 15 min (Fig. 3B) . The Figure 3D shows that the [ 3 H]PtdBut response of the PAC 1-null receptor was inhibited to a greater extent than that of the PAC 1-hop1 receptor by the PLC inhibitor U 73122; the converse of their sensitivity to BFA and consistent with a greater contribution of a PLCdependent pathway to the PAC 1-null receptor response.
PAC 1-null and PAC 1-hop1 receptors were cotransfected with ARF1-HA into COS 7 cells and receptor:small G protein coimmunoprecipitation was investigated in HA-directed immunoprecipitates. These were probed for specific 125 I-PACAP-27 binding sites because suitable high-affinity PAC 1 receptor antibodies are not available. The solubilization procedure extracted similar levels of specific 125 I-PACAP-27 binding sites from PAC 1-null and PAC 1-hop1 receptor-expressing cells (i.e., approximately 100 fmol/ml extract), as assessed by PEG precipitation binding assays, but no detectable specific binding in extracts of untransfected cells. With extracts of PAC 1-hop1 but not PAC 1-null receptor-expressing cells, increasing levels of anti-HA IgG in the immunoprecipitation gave a concentration-dependent increase in the amount of specific 125 I-PACAP-27 binding recovered in the precipitate (Fig. 3E) . Under the present experimental conditions, prein- 4.1 Ϯ 0.5 7.9 Ϯ 0.9 6.0 Ϯ 0.5 4.5 Ϯ 0.4 cubation with agonist did not seem to be a prerequisite for this association. The overall levels of IgG were kept constant by substitution of nonimmune mouse IgG. Chimeric VPAC 2 /PAC 1 Receptors. To address the importance of the i3 sequence of the PAC 1 receptor splice variants in determining the route and extent of coupling to PLD, we constructed chimeric VPAC 2 /PAC 1 receptors (Fig. 4) . These contained the body of the VPAC 2 receptor with a segment from tm5 to tm7 (i.e., including the i3 domain) derived from either PAC 1-null or PAC 1-hop1 receptor sequences. Thus, the only difference between these two constructs was the additional 28 amino acid hop-1 cassette in the VPAC 2 /PAC 1-hop1 construct.
The chimeric receptors were transiently expressed in COS 7 cells for assessment of their signaling responses and transfected GLP-1 receptors were also studied for comparison. Both VPAC 2 / PAC 1-null and VPAC 2 /PAC 1-hop1 receptor constructs mediated robust cAMP responses to VIP (mean maximal responses of 149-and 143-fold of basal and EC 50 values of 0.8 Ϯ 0.1 and 1.5 Ϯ 0.2 nM, respectively; means Ϯ S.E.M., n ϭ 6; Fig. 5A ). The potency of these responses was less than in CHO cells (as described previously for wild-type PAC 1 and VPAC 2 receptors in COS 7 cells (Lutz et al., 1999) . This may relate to different complements of relevant cellular proteins in the two cell types. GLP-1 (7-36) amide potently activated cAMP production (in GLP-1 receptor-expressing cells only) with an EC 50 value of 0.034 Ϯ 0.014 nM (mean Ϯ S.E.M., n ϭ 6). (Fig. 5B) . Although the EC 50 values were greater than those for cAMP production, they were in the low nanomolar range (2.5 Ϯ 1.7 and 5.6 Ϯ 3.9 nM for the VPAC 2 /PAC 1-null and VPAC 2 /PAC 1-hop1 constructs, respectively, means Ϯ S.E.M., n ϭ 6-10). The corresponding maximal response values were also similar; 3.2 Ϯ 0.2-and 2.5 Ϯ 0.4-fold of basal, respectively. The GLP-1 receptor mediated a [ 3 H]PtdBut response only at very high concentrations of GLP-1 (7-36) ]PtdBut responses of the receptors were challenged with BFA, only that of the VPAC 2 / PAC 1-hop1 construct was significantly inhibited at BFA concentrations of 50 M and above (Fig. 5C ). This is consistent with the idea that transfer of the PAC 1-null or PAC 1-hop1 i3 domains into the body of the VPAC 2 receptor had respectively conferred ARF-independent and ARF-dependent coupling to PLD activation.
Native VPAC 2 and PAC 1 Receptors. To assess whether similar mechanisms for PLD activation might occur in native cells, we examined responses of the VPAC 2 receptor in GH 3 cells and the PAC 1 receptor in ␣T3-1 cells. In each case these are the only members of the VPAC/PAC receptor family expressed, and the predominant form of the PAC 1 receptor in ␣T3-1 cells is known to be the hop-1 splice variant (Rawlings et al., 1995; MacKenzie et al., 2001 ). In GH 3 cells, VIP elicited a robust cAMP response with an EC 50 value of 1.9 Ϯ 0.4 nM and a maximal response 7.6 Ϯ 0.4-fold of basal. A smaller PLD response was also seen, with an EC 50 value of 30.6 Ϯ11.2 nM and maximal response of 2.6 Ϯ 0.1-fold of basal (means Ϯ S.E.M., n ϭ 6) (i.e., only around 12-fold lower potency than the cAMP response) (Fig. 6A) . In ␣T3-1 cells, PACAP-38 elicited cAMP production with an EC 50 value of 0.19 Ϯ 0.13 nM and maximal response 12.1 Ϯ 0.5-fold of basal. PLD was also clearly activated with an EC 50 value of 6.7 Ϯ 1.0 nM and a maximal response 3.2 Ϯ 0.1-fold of basal (means Ϯ S.E.M., n ϭ 6) (i.e., approximately 35-fold lower potency than the cAMP response but still within the low nanomolar range of ligand concentration) (Fig. 6B) . Both PLD responses were sensitive to BFA with mean IC 50 values of 64 M for the VPAC 2 receptor in GH 3 cells and 65 M for the PAC 1 receptor in ␣T3-1 cells (Fig. 6C) , concurring with the properties observed for VPAC 2 and PAC 1-hop1 receptors in transfected cells.
Discussion
Like other GPCRs in the secretin/parathyroid hormone receptor family (Probst et al., 1992; Segre and Goldring, 1993; Harmar and Lutz, 1994; Donnelly, 1997) , the PAC 1 and VPAC receptors increase cellular cAMP levels, presumably via coupling to Gs. VPAC 1 , VPAC 2 , and PAC 1 receptors expressed here in CHO cells mediate robust increases in cellular cAMP levels but in addition can lead to the activation of PLD (and in some cases, PLC). cAMP signals occur at higher potency than phospholipase activation in all the receptors studied here, but substantial phospholipase activation still occurs at low nanomolar concentrations that are potentially relevant in a physiological context.
Neither the potency nor maximal response of cAMP production was altered by the presence of the hop1 cassette in i3 of the PAC 1 receptor (compared with the PAC 1-null form). Similar numbers of receptors were expressed both at the cell surface and in pools internalized from the cell surface in the PAC 1-null and PAC 1-hop1 CHO cells, matching their similar cAMP responses. In the VPAC 1 receptor CHO cells, receptor expression was lower than that in VPAC 2 and PAC 1-null or PAC 1-hop1 cells and the maximum but not the potency of the cAMP response was diminished.
PAC 1 receptors activate PLC (through a pertussis toxin-in- M VIP) , or at the GLP-1 receptor (OE) (induced by 10 M GLP-1 (7-36) amide), n ϭ 6. Statistical significance of the inhibition was assessed by Mann-Whitney U test; *p Ͻ 0.05. sensitive route) in a variety of cell types (Deutsch and Sun, 1992; Spengler et al., 1993; Schomerus et al., 1994; Pantaloni et al., 1996; Pisegna and Wank, 1996; van Rampelbergh et al., 1997) . Rat PAC 1-null and PAC 1-hop1 receptors expressed in LLC-PK1 cells activate PLC with similar potency (Spengler et al., 1993) although other splice variants, the hip form and an Nterminally deleted form show reduced, and facilitated, potency of PLC activation, respectively (Spengler et al., 1993; Pantaloni et al., 1996) . Human PAC 1-null and PAC 1-SV-2 (equivalent to hop1) receptors expressed in NIH/3T3 cells display similar potencies of PLC activation but the PAC 1-SV-2 variant gave a greater maximal response when expressed at similar levels of total receptors per cell (Pisegna and Wank, 1996) . In the present study, the PLC response of the rat PAC 1-null receptor in CHO cells was greater than that of the PAC 1-hop1 variant for similar levels of receptor expression. Both species differences and host cell differences may contribute to the disparity.
In contrast, VPAC 1 and VPAC 2 receptors are less well known to activate PLC. Both receptors can elicit a modest PLC response (which is partly sensitive to pertussis toxin) when expressed in COS 7 cells (MacKenzie et al., 1996 (MacKenzie et al., , 2001 ). In addition, another group reported a 1.5-fold increase in phosphoinositide hydrolysis in CHO cells expressing the VPAC 1 receptor (van Rampelbergh et al., 1997 The activation of PLD by members of the secretin/parathyroid hormone receptor family has been little studied, although it has been reported in the case of glucagon, calcitonin, and parathyroid hormone receptors (Pittner and Fain, 1991; Friedman et al., 1999; Naro et al., 1998) . This is the first report of PLD activation by the VPAC 1 , VPAC 2 , PAC 1-null , and PAC 1-hop1 receptors. Unlike the PLD responses of many rhodopsin family GPCRs there was no evidence for rapid desensitization, but a variety of factors, including assay conditions, cellular context, and receptor type could contribute to this and the issue was not further investigated here. Both VPAC 1 and VPAC 2 receptors mediated modest PLD responses to VIP (with a lower maximal response for the VPAC 1 receptor, matching its lower level of expression). Similar nanomolar potencies were seen at both receptors although these were much weaker than the effects on cAMP production. PLD activation could not be mimicked by activators of Gs or adenylate cyclase and occurred in the absence of any detectable PLC responses, suggesting that activation of PLD did not occur downstream of either of these pathways. A lack of concurrent PLC activation was also seen with the glucagon receptor (Pittner and Fain, 1991) , whereas PLD activation by the parathyroid hormone receptor was unaffected after the inhibition of PLC activity by U 73122 (Friedman et al., 1999) . Instead, both VPAC 1 and VPAC 2 receptor PLD responses were inhibited with relatively high potency by the ARF inhibitor BFA, whereas cAMP responses of the VPAC 2 receptor, for example, were unaffected. These data are consistent with the physical association between VPAC receptors and the small G protein ARF demonstrated in Fig. 1E (a link that could potentially provide a basis for facilitated ARF-dependent PLD activation). Both PAC 1-null and PAC 1-hop1 receptors also displayed PLD responses and although these were again of lower potency than cAMP responses, they were of similar (or greater) potency than the PLC responses of the receptors. The PLD response of the PAC 1-null receptor (but not the hop1 variant) was inhibited by low concentrations of the PLC inhibitor U 73122, suggesting that it may result substantially from PLCdependent pathways. In contrast, the PAC 1-hop1 receptor displayed a much greater maximal PLD response that (unlike that of the null variant) was sensitive to BFA, whereas its cAMP and PLC responses were unaffected. This suggests that the presence of the hop1 cassette is critical in linking the PAC 1 receptor to an ARF-dependent route of PLD activation. Correspondingly, immunoprecipitation of epitope-tagged ARF1 resulted in coprecipitation of PAC 1-hop1 but not PAC 1-null receptors (Fig. 3E) .
Chimeric VPAC 2 /PAC 1 receptors containing either PAC 1-null or PAC 1-hop1 i3 domains were constructed to address whether BFA-sensitivity/insensitivity could be conferred just by an i3 domain swap. The chimeric VPAC 2 /PAC 1 receptors with i3 domains from either PAC 1-null or PAC 1-hop1 receptors showed no apparent difference in their cAMP responses. However, the VPAC 2 /PAC 1-null construct (just like the wildtype PAC 1-null receptor) showed a PLD response insensitive to BFA, despite the main body of the construct, apart from i3, being of VPAC 2 (BFA-sensitive) origin. The VPAC 2 /PAC 1-hop1 chimera retained BFA sensitivity, indicating that the i3 sequence of PAC 1 receptors is a critical determinant of coupling to ARF-dependent PLD activation. Some analogy can be drawn with the dopamine D 2 receptor, where i3 splice variants couple differentially to G ␣i2 (Guiramand et al., 1995) and the calcitonin receptor where i1 variants couple differentially to PLC but not to AC (Nussenzveig et al., 1994) . Thus, the alternative splicing of receptors may allow a more subtle selection of signals and hence control of cellular activity to be achieved. Analogous behavior of natively expressed VPAC 2 and PAC 1 receptors was demonstrated using GH 3 and ␣T3-1 cell lines, respectively (Fig. 6 ). Modest but significant PLD responses to agonists were seen in each case with sensitivity to BFA (matching in the case of ␣T3-1 cells, their predominant expression of the hop-1 splice variant (Rawlings et al., 1995) . A number of studies have pointed to a role of amphipathic helical domains incorporating basic amino acids in the coupling of GPCRs to G proteins. Peptides derived from the ␣ 2 -adrenergic receptor activate G i/o in vitro, providing they possess basic amino acids spaced throughout the peptide and end with a BBxxB or BBxB (where x is any residue, and B is basic residue or in the last position either a basic or aromatic residue) (Ikezu et al., 1992; Wade et al., 1996) . Groupings of basic and hydrophobic amino acids, situated in i3 of the muscarinic and the ␣ 2 -adrenergic receptors, have been implicated in interactions with G proteins (Burstein et al., 1998; Okamoto and Nishimoto, 1992; Wade et al., 1996; Wess, 1997) . The VPAC 2 receptor contains a classical BBxxB motif at the i3/tm6 junction, whereas both the VPAC 1 and PAC 1-hop1 receptors contain a motif similar to that seen in the ␣ 2 -adrenergic receptor with spaced basic residues and a cluster of basic amino acids upstream of tm6. The presence of the hop-1 insert in the PAC 1 receptor provides the cluster of basic amino acids that completes a spaced basic residue motif. The PAC 1-null receptor has no classical or spaced base motif present in its i3 and this may potentially underlie its minimal ARF-dependent coupling to PLD.
In summary, the VPAC and PAC 1 receptors can activate PLD and although this is at higher concentrations of agonist than those required to elicit cAMP production, they may still be physiologically relevant. There are marked differences in the mechanisms apparently used to bring about this activation, with both ARF-dependent routes and PLC-dependent routes being implicated in different cases. From data with i3 splice variants of the PAC 1 receptor and with chimeric receptor constructs incorporating i3 domain swaps it seems that the i3 structure of the PAC 1 receptor is a critical determinant of both its physical association with ARF1 and its ARFdependent coupling to PLD.
